Additional Study Information: The purpose of the first part of this study, the Dose Escalation part, is to study and identify the highest tolerable safe dose of MORAb-202. Not all patients will get the same dose of the study drug. At the beginning of the study, a small group of three to six patients will receive an infusion with a low dose of the study drug. If this dose does not cause severe side effects, it will be increased for each new group of patients who participate in the study and will continue until the highest tolerable safe dose of the drug is confirmed. This dose will be selected and used as the starting dose for each patient in the Expansion part. The purpose of the Expansion part is to further investigate how the different tumor types being studied respond to the study drug and to gather more information on its safety and effectiveness.